We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Medica Group Plc | MGP | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 211.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 211.00 | 211.00 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 24/4/2023 07:58 by ali47fish mgp takeover offer 212p up 31pc today |
Posted at 17/1/2023 12:56 by kalai1 Medica Group plc issued a trading update for FY22 and an outlook for FY23 this morning. Medica had a strong performance for the second half of the year across the Group driven in particular by UK Elective revenues returning to expected levels. Group revenue of £77.0 million for the twelve-month period ending 31 December 2022 was in-line with market expectations and represents an increase of 24% over 2021. Gross margins also remained resilient at 48%, operating profit is expected in line with expectations. The balance sheet is solid, Medica had £0.5 million of net cash at 31 December 2022. Medica continues to evaluate strategic acquisition opportunities to expand the scale and therapeutic focus of its clinical trials business, as well as to accelerate wider growth and differentiation of the business while also continuing to focus on new areas of organic growth. Valuation is attractive, profitability is high and the business has a solid history of growth. BUY......from WealthOracle |
Posted at 27/9/2022 08:14 by adorling Strong results across the board and demand still increasing.hard to understand the 8% decline at the open? This market is so frustrating but patience will out for LTH’s eventually and we have a another dividend to collect. |
Posted at 25/10/2021 11:11 by bountyfull More diagnostic tests without more radiologists ensures a very strong tailwind for MGP. Hospitals are renting more equipment at the moment and plonk it carparks etc. At St Mary's in Paddington we then send some of this off to be read to ensure we keep up. I can see the need to do that increasing because the last thing you want is expensive machinery not being used especially when there is a clinical need. |
Posted at 10/6/2021 11:23 by mighunter Liontrust had borrowed shares returned to them yesterday... Jupiter closing short? Judging by price, big buy of 887,800 shares just gone through the books. Liberum this morning reiterates Medica as joint top pick in Medical sector, alongside Puretech, with MGP buy and price target of 235p vs 220p previously. Hoping we can make good progress through gap above between 170-190p. |
Posted at 14/5/2021 09:20 by tomps2 David Thornton speaks on Medica’s (MGP) results at 21:59 in the latest piworld interviewWatch the Video here: Or listen to the Podcast version: |
Posted at 15/4/2021 10:33 by mighunter Good overview of the company - Interview with Stuart Quin CEO. Also see on BBC that NHS operation waiting lists just hit 4.7m, highest since 2007. MGP sorely needed in future. HTtps://www.share-ta |
Posted at 24/3/2021 20:01 by mighunter Did anyone else notice/can give explanation to the near minute by minute buys today in MGP, at deal sizes averaging about 160 shares per trade? Near continual throughout the day, most unlike MGP normal trading pattern? Someone accumulating?? |
Posted at 24/1/2021 16:50 by adamb1978 Hi DaveThe challenge with looking at 2020 for MGP is that it was badly impacted by covid. That's going to have a huge impact on EPS and therefore the FY20 multiple will look high. Obviously if you believe that the covid-impacted FY20 represents the new-norm for MGP then it might be an appropriate basis for valuation, but in my view it will recover back to where it was pre-covid and continue the similar growth of pre-covid. Therefore, combined with the fact that you buy shares based on the future performance and cashflows, in my view FY20 results are largely irrelevant for valuing MGP. To answer your question, the broker forecasts which I see for them for FY20 show 3.6p EPS. Cheers, Adam |
Posted at 24/1/2021 10:48 by discodave45 Hi Adam,Thanks for your views on MGP, have been looking at similar growth potential for this sector and had a cursory look at MGP. However I felt it was priced about right even for the anticipated recovery in FY21 (PE 15), for FY20 it's siting on a rating of 50 (if my eps calc of about 2.5p is correct).All the best though as who knows how MGP will do in the next few years but not for me on valuation, good luck. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
